Skip to main content

Pharma News

academics

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Lupin acquires Huminsulin from Lilly to Enhance Diabetes Portfolio

    Global pharma major Lupin Limited announced the acquisition of Huminsulin® in India from Eli Lilly and Company to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin range of products comprising of Insulin Human, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, through existing Distribution and Promotion Agreements with Lilly, India.
  • Halozyme Announces FDA approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE

    Halozyme Therapeutics, Inc announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) co-formulated with Halozyme's ENHANZE® drug delivery technology for subcutaneous use in most previously approved adult, solid tumor intravenous (IV) Opdivo® indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy® (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib.

  • New scan method unveils lung function secrets

    The scan method has enabled the team, led by researchers at Newcastle University, UK, to see how air moves in and out of the lungs as people take a breath in patients with asthma, chronic obstructive pulmonary disease (COPD), and patients who have received a lung transplant.

  • Mankind Pharma to launch Sintilimab, advanced cancer treatment, in India

    Mankind Pharma Limited and Innovent Biologics have announced a groundbreaking partnership to exclusively license and commercialise sintilimab, an advanced PD-1 immunotherapy, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.

  • Akums signs agreement of Rs. 1760 crore to supply pharmaceuticals in Europe

    Akums Drugs and Pharmaceuticals has entered into an agreement with one of Leading Global Pharma Company for Manufacture and Supply of selected pharmaceutical formulations in the European Market. Akums group will manufacture and supply Oral Liquid Formulation to be marketed in multiple European countries.

  • U of T researchers develop tool to fast-track measurement of protein interactions for drug discovery

    A team led by researchers at the University of Toronto has created a platform, called SIMPL2, that revolutionizes the study of protein-protein interactions by simplifying detection while improving measurement accuracy.

  • New Drug to Prevent Migraine May Start Working Right Away
    A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, 2024, online issue of Neurology, the medical journal of the American Academy of Neurology. The study looked at the drug atogepant, which is a calcitonin gene-related peptide CGRP receptor antagonist taken by mouth.
  • Microtech Announces First Human Case of Implantable Microsensor for Heart Failure

    Microtech, a wholly owned subsidiary of Medinol Inc., a leader in global MedTech research and development, announced that it has initiated human clinical trials of their microsensor platform, in a trial to measure atrial pressures important for the treatment of heart failure. The first implantation was recently performed by Prof. Erez Sharoni at Beilinson Medical Center in Petah-Tikva, Israel.

  • Kumar Organic Visits Customers in Egypt
    A team from Kumar Organic comprising of Mr. Vinay Kumar Singh, Head-Formulation and Ms. Aksha David, Sales Manager-MEA visited esteemed customers in Egypt Cairo & Alexandria from 15th to 19th December 2024, alongwith representative of their distributer Manapharma, Eng.Mary Waguih Zaki, Chem.Fady Fathy and Mayan El Menshawy.
  • FDA approves Zepbound as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
    Eli Lilly and Company announced the U.S. Food and Drug Administration approved Zepbound tirzepatide as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea OSA and obesity.
Subscribe to Pharma News